Patent lawyers began breathing again Wednesday, as the specter of new patent rules was chased away, at least for a little while, by a Virginia court. A federal judge granted GlaxoSmithKline’s motion for a preliminary injunction blocking the U.S. Patent and Trademark Office from implementing rules set to go into effect today. The new rules would reduce the number of claims, which help define a patent, and the number of continuations, which are used to amend patent claims and contest those that are rejected.
Sorry, the comment form is closed at this time.